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ABSTRACT 
Objectives 
Patients with systemic vasculitis (SV) have an increased risk of all-cause mortality, often due to 
infection, compared to the healthy population. We investigated whether humoral response to 
vaccination  and biomarkers of immune dysfunction were associated with infection and death. 
 
Methods 
Patients with SV in remission were vaccinated with  pneumococcal 7-valent conjugate, 
Haemophilus influenzae type B and Meningococcal group C conjugate vaccine and Meningococcal 
polysaccharide groups A, C, Y and W135 vaccines. Total IgG and antibody titres against specific 
antigens and lymphocyte subset analysis were performed before vaccination. Post vaccination 
antibody titres were measured at 4 weeks and 2 years from which an antibody response score was 
calculated. Infections and death following vaccination were collected prospectively following 
vaccination. 
 
Results 
92 patients were safely vaccinated  with no increase in disease relapse, median follow-up 4.6 (3.6-
4.8) years. Eighteen patients died at a median of 2 years and the overall infection rate was 0.4 
(0.2-1.3) infections/patient/year. Reduced  serum IgG, B cell and CD4+ cell counts predicted poor 
vaccine response and infection but not death. The response rates to individual vaccine antigens 
was highly variable, median response rate of 46% (interquartile range 39-58%) of patients 
3 
 
responding to each individual antigen. Vaccine response,  age and reduced renal function were 
independent predictors of all-cause mortality in multivariate analysis.  
 
Conclusion 
Total IgG and B cell counts predict infection and response to vaccination. Vaccination in patients 
with SV in remission is safe and the response predicts all-cause mortality. Vaccine response is a 
surrogate marker of immune system health.  
Significance and Innovations: 
 In patients with systemic vasculitis in remission there needs to be a balance of risk between 
the side-effects associated with immunosuppression and disease activity. This balance must 
be individualised to each patient but this is often difficult . Measurement of total IgG and B 
cell counts in patients with systemic vasculitis in remission helps identify those most at risk 
of infection. 
 This study identifies that the humoral response to vaccination predicts those at greatest risk 
of all-cause mortality, with the commonest cause of death being infection. 
 Vaccination in this group of patients is safe 
 Humoral response to vaccination, total IgG level and B cell counts taken together may 
identify a subset of patients who are at greatest risk from the side-effects of 
immunosuppressive therapy.  
4 
 
 
Despite improved treatments, patients with systemic vasculitis continue to have increased all-cause 
mortality compared to healthy individuals. Specifically, patients with ANCA-associated vasculitis 
have a 2.6 mortality ratio compared with the healthy population, with infection being the most 
frequent cause of death[1], and associated with prolonged use of immunosuppression.  Infection is 
also an important cause of morbidity. In the first year following diagnosis, when immunosuppression 
is at its highest,  25% of patients with systemic vasculitis had an infection episode[2].  Although 
infection risk reduces with time in these patients, it remains elevated compared to the healthy 
population. The risk of admission to hospital with pneumonia, a vaccine preventable illness, in these 
patients is increased at  up to 5 times that of an age matched healthy population[3]. Identification 
and prevention of those at high risk of side-effects associated with therapy is essential to improve 
outcomes in these patients. 
 
Cumulative immunosuppression[4], age and severity of renal impairment [2], are important risk 
factors for infection and mortality. However no immune biomarkers, beyond leucopenia[5], have 
been shown to help identify those with poor functional immune systems and increased risk of 
infection.  Vaccination is not only therapeutic but also provides information on the health of the 
immune system. Vaccination is recommended for immunosuppressed patients to prevent infection; 
however the immune response is often poorer than in healthy controls[6]. Failure to mount an 
effective response to vaccination along with detailed investigation of the immune system may 
identify those patients most at risk of infection and death.  
 
The aim of this study was to investigate whether detailed investigation of the immune system and 
the immune response to vaccination in patients with systemic vasculitis predicted all-casue mortality 
and risk of infection.  
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METHODS 
Patients were identified from the vasculitis clinic lists at University Hospitals Birmingham NHS 
Foundation Trust (UHBFT). Patients had a diagnosis of small or medium sized systemic vasculitis 
(graunulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis  with 
polyangiitis or classical polyarteritis nodosa) and had not received pneumococcal or haemophilus 
influenza vaccine within the previous 5 years. Following the introduction of routine vaccination in 
the clinic in 2009 patients were consented for the use of their clinical data.  All patients gave 
informed consent and the study protocol was approved by the West Midlands Research Ethics 
Committee (10/H1208/13). 
Patients were eligible for vaccination if they had been in stable remission > 6 months (Birmingham 
Vasculitis Activity Score=0); had received cyclophosphamide and steroid induction therapy but not 
within 6 months; had not received rituximab within 6 months; were on ≤ 10mg prednisolone per 
day; currently treated with no more than one immunosuppressant in addition to prednisolone; had 
no active infection; were not pregnant and had no history of previous severe adverse reaction to 
vaccination or received vaccination with the proposed vaccines. Clinical and laboratory data were 
recorded from patient records. Infection episodes following vaccination were prospectively 
identified from patient notes. Severe infections were defined as requiring admission to hospital 
and/or intravenous antibiotic therapy. Patients requiring intravenous immunoglobulin (IVIg) were 
excluded from the study. Causes of death during follow up were determined from death certificate 
data. 
Patients had blood collected immediately pre-vaccination for lymphocyte subset analysis by flow 
cytometry (CD3, CD4, CD8, CD19, CD16, CD56; all Becton and Dickinson, Oxford, UK) and total 
immunoglobulin G (IgG) assayed by nephelometry by the Clinical Immunology Laboratory (CIL) at the 
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University of Birmingham. Vaccinations given were; 0.5ml pneumococcal (Pn) 7-valent conjugate 
vaccine (Prevnar; Pfizer, Surrey, UK ) intra-muscular injection; 0.5ml Haemophilus type b (HIb) and 
Meningococcal (Men) group C conjugate vaccine (Menitorix) intra-muscular injection at time 0; 
0.5ml Meningococcal polysaccharide groups A, C, Y and W135 vaccine (ACWY Vac) deep subcutaneous 
injection administered four weeks later (both GlaxoSmithKline, Uxbridge, UK) . Serum was collected 
immediately pre-vaccination for antibody titres and at 4 weeks and 2 years following each 
vaccination to assess response. 
Antibody titres against Pn, HIb and Men were assayed by the CIL using a multiplex assay which is 
externally quality assured by United Kingdom National External Quality Assessment Service, 
Sheffield, UK[7]. Serum was separated from blood and frozen at -20°C until analyzed. There is 
inherent variability in functional antibody testing so to minimise inter-assay variability samples were 
batch analysed such that all samples from an individual patient were included in the same analysis. 
For antibody titre threshold analysis Pn titres >0.35 ug/ml, Men titres >2 ug/ml and HIb >1 ug /ml 
were considered to be above threshold. It is unknown what a protective pneumococcal antibody 
titre is in adults and may vary according to serotype and published concentrations vary from 0.15 – 2 
ug /ml. A cut off of 0.35 ug /ml is recommended by World Health Organisation for infants and is used 
widely in the UK for adults. 
Antibody response scores were calculated using the formula 
100 ∗
(𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑖𝑒𝑠 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑇 >𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑− 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑟𝑒𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑖𝑜𝑛 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑖𝑒𝑠>𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑)
(12 − 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑖𝑒𝑠 𝑝𝑟𝑒𝑣𝑎𝑐𝑐𝑖𝑛𝑎𝑡𝑖𝑜𝑛>𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑)
  
We assessed response as the proportion of below “protective” threshold antibody titres that 
changed to above threshold titres following vaccination. Where 12 is the total number of antibody 
titres measured for each patient and T is time post vaccination. Patients with all 12 antibody titres 
>threshold, could not improve their response from  pre-vaccination levels (n=5) and were excluded 
from this analysis. 
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Statistical analysis 
Continuous data is presented as median (inter-quartile range) unless stated. Categorical variables 
are presented as number (percentage). Differences between groups were analysed by Mann-
Whitney, Wilcoxon signed rank or Kruskal-Wallis tests for continuous variables or by Pearson’s Chi2 
test with Yates’ correction for discrete variables as appropriate. Correlations were tested using 
Spearman’s Rank method. Survival analysis was performed using Cox regression and is reported as 
hazard ratio (HR) and 95% confidence interval (95%CI). Statistical analysis was performed using SPSS 
version 20 (IBM, Portsmouth, UK). P values <0.05 were considered significant. This was an 
exploratory observational cohort study and no formal power calculations were included. Our 
primary analysis was vaccine response with factors predicting that response secondary outcomes. 
RESULTS 
Ninety two patients were vaccinated and had clinical and laboratory follow up. The demographic 
details of the participants are shown in table 1. Median patient follow up post vaccination was 4.6 
(3.6-4.8) years and total patient follow up was 363 patient years; none were lost to follow up. 
Eighteen patients died during follow up at a median of 2 (0.6-3.0) years post vaccination. Causes of 
death were infection (n=8) ,cardiovascular disease (n=3), cancer (n=3) and kidney disease (n=4). 
Lymphocyte phenotyping was incomplete in eight patients; their vaccine responses are reported 
with their clinical details and follow up but they are not included in the analysis of lymphocytes 
subsets associated with vaccine responses.  
Nine patients had previously received rituximab at a median 1.8 (1.2 – 2.6) years prior to 
vaccination. At the time of vaccination 81 patients were still taking prednisolone at a median of 5 (5-
10) mg/day. Seven patients had discontinued immunosuppression prior to vaccination.  
During follow up 70 patients experienced 268 infections and 35 patients experienced 56 serious 
infections (defined as hospital admission and/or iv antibiotics). The commonest infections were 
8 
 
lower respiratory tract (n=116), upper respiratory tract (n=42), urinary tract (n=39), fungal and 
bacterial skin and mucosal infections (n=30) and gastrointestinal infections (n=16). There were only 
two reported episodes of herpes zoster infection. Other infections included osteomyelitis (n=2), 
dialysis related peritonitis (n=1), non-specific viral infections (n=20) and two episodes of bacteremia 
without an identified source. There were no episodes of pneumocystis jirovecii. 
The median infection rate was  0.4 (0.2-1.3) per  patient per year for all infections and 0 (0-0.2) 
serious infections per patient  per year following vaccination.  The overall infection rate for the 
cohort was 0.7 infections per year and 0.2 serious infections per year. Vaccination was safe. There 
were no adverse events reported immediately following vaccination. There was no change in the 
relapse rate in the two years following vaccination (pre-vaccination 0.15 per patient year; post-
vaccination 0.12 per patient year; p>0.05).  
Immune biomarkers predict infection 
At the time of vaccination all patients had a total white cell count within the normal range with 
normal neutrophil and NK cell counts. The median total lymphocyte count was low, with low CD3+ T 
cells and CD19+ B cells (table 1). Thirty seven percent of patients had CD4+ cell counts less than the 
lower limit of normal and 44% patients had CD8+ cell counts below the normal range. Twenty two 
percent of patients had low IgG levels. Serum IgG concentration correlated with B cell count 
(cc=0.33; p=0.002), and CD4 count (cc=0.3; p=0.005). 
B cell count correlated negatively with previous cumulative cyclophosphamide exposure (cc=-0.29; 
p=0.012); CD4 count correlated negatively with age (cc=-0.35; p=0.001); both B cell count and CD4 
T cell count correlated positively with eGFR (cc=0.25; p=0.022 and cc=0.35; p=0.001 respectively).  
Overall infection rates correlated negatively with serum IgG (r= -0.27; p=0.01), CD4 cell count (r=-
0.22; p=0.049) and B cell count (r= -0.22; p=0.046) (supplementary figure 1). The serious infection 
rate correlated negatively with eGFR (r=-0.23; p=0.028), B cell count (r=-0.27; p=0.014), and CD4 T 
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cell count (r=-0.25; p=0.021). CD8+ cell counts correlated negatively with age (r=-0.27; p=0.013) but 
there was no correlation with the infection or serious infection rates, renal function or cumulative 
corticosteroid or cyclophosphamide use.  
Patients on maintenance immunosuppression at the time of vaccination had lower B cell counts, CD4 
T cell counts and serum IgG concentrations but higher eGFR than patients on steroids only or no 
maintenance therapy (figure 2), suggesting a more dysfunctional immune system. There was no 
difference in CD8+ counts between those still on maintenance immunosuppression and those who 
had discontinued it. 
Patients on maintenance immunosuppression had more infections per year during follow up (0 (0-
0.2) vs 0. 6 (0.2-1.5); p=0.0001) although there was no difference in the serious infection rate 
between patients on maintenance immunosuppression and those who had discontinued 
immunsuppression (0 (0-0.2) vs 0 (0-0.2); p=0.7). Previous cumulative steroid dose correlated with 
the overall infection rate (r=0.21; p=0.043) but not the serious infection rate (r=0.18; p=0.097). 
There was no difference between patients still on immunosuppression and those who had 
discontinued with regards to age and previous cyclophosphamide or steroid use. There was no 
relationship between previous cumulative cyclophosphamide use and the infection or serious 
infection rate. There was no correlation between age and all infections but there was a non-
significant correlation between age and the serious infection rate (r=0.2; p=0.056). 
Vaccine Response 
The median antibody titres for all the vaccine components increased at 4 weeks post vaccination 
(supplementary table  1) whereas there was no significant change in the antibody titres against Pn1, 
Pn3, Pn5 and Pn7 which were not included in the 7-valent conjugate vaccine. At four weeks post 
vaccination there was a significant improvement in the percentage of patients who had antibody 
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titres above the threshold, although there was variability in the response between antigens 
(antibody response above the “protective” threshold for each antigen median 46% (interquartile 
range 39-58%)(table 2).  
Serum was available for antibody assay from 64 patients two years after vaccination. Although there 
was a statistically significant reduction in the antibody titres for some antigens after two years (Pn4, 
Pn6B, Pn9V, Pn18C, Pn23F, MenC & MenY; supplementary table 2) There was no change in the 
percentages of patients with protective antibody titres against any antigen except for MenC (38% vs 
20%; p=0.032).  
Better vaccine responses are associated with a more “intact” immune system 
Patients with higher CD4+ and CD19+ cell counts and higher serum IgG had better responses to 
vaccination. Vaccine response scores correlated with serum IgG concentration (r=0.34; p=0.001), B 
cell count (r=0.36; p<0.001) and CD4 cell count (r=0.24; p=0.028)(supplementary figure 1). 
 Patients on no immunosuppression had better vaccine response scores than patients still on 
maintenance immunosuppression (75 (25-88)% vs 50 (17-60)%; p=0.042). The response score did not 
correlate with patient age, cumulative cyclophosphamide or steroids or eGFR. There was no 
correlation between the total infection rate or the serious infection rate and vaccine response 
scores. 
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Poor vaccine response is associated with a higher risk of all-cause mortality  
The median vaccine response score was 46%. Patients were classified into those with a vaccine 
response score >50% or <50%. Kaplan-Meier survival analysis demonstrated that patients with 
vaccine response scores >50% had better survival than those with vaccine response scores less than 
50% (figure 1). 
In Cox regression multivariable survival analysis increased age, poor renal function and reduced 
response to vaccination were significantly and independently associated with increased risk of all- 
cause mortality (table 3). In this cohort of patients in established stable remission the overall and 
serious infection rates post vaccination predicted survival in the univariable survival analysis 
(supplementary table 4) but not the multivariable analysis. Patients who subsequently died from 
infection had significantly worse vaccine response scores than patients who were alive at the end of 
follow up (29% (5-42%) vs 50% (25-74%); p=0.044) although this was not significantly different to 
patients who died from other causes (33% (20-40%); p=0.8). 
 
DISCUSSION 
All-cause mortality and infection remains increased in patients with systemic vasculitis compared to 
the general population [1, 2, 8]. This study identifies that low IgG and low B cells, immunological 
biomarkers, are associated with infection and vaccine response  in patients with systemic vasculitis 
in stable remission on maintenance immunosuppression. Low CD4 counts were associated with 
severe infection. This study confirms the association of poor renal function and continued 
immunosuppression with increased risk of infection.  Although a poor response to vaccination was 
not associated with infection risk it was identified as an important predictor of all-cause death in 
patients with systemic vasculitis, independent of age and renal function.  
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Surprisingly, despite patients being in stable remission for at least 6 months from the time of last 
receiving cyclophosphamide, a large percentage remained lymphopenic, particularly with 
pronounced B cell lymphopenia. The negative  correlation of B cell counts with prior 
cyclophosphamide exposure suggests that the effects of cyclophosphamide on the immune system 
are long lasting The association of lymphopenia and low CD4+ counts with immune dysfunction and 
infection has been reported but this study extends  understanding by clearly showing  the 
association of low B cell counts with infection and poor vaccine response in this population.  
Only 9 of our patients had received rituximab and all at least 6 months prior to vaccination. It is well 
known that rituximab reduces the efficacy of vaccination, especially if given within the first few 
months post rituximab treatment [9]. This study suggests that B cell depletion due to other causes, 
such as cyclophosphamide, also influence the efficacy of vaccination, along with low IgG levels and 
CD4+ cell counts. We have also identified effects of anti-proliferative immunosuppressants on 
vaccine responses. This differs to previous GPA patients vaccinated with influenza, which showed no 
effect of immunosuppressive therapy[10]. The effect seen in our study may be due to differences in 
vaccines used and the larger cohort size in our study.  
The response of patients to individual antigens was poor with fewer than 50% of patients responding 
to most antigens.  A poor response to the vaccination was indicative of poor immunological function 
with low IgG, B cell counts and CD4+ T cell counts predicting vaccine response score. Those patients 
with a poor vaccine response were more likely to be on maintenance immunosuppression. This 
study extends previous findings that identified low CD4+ T cell counts as a risk for lack of humoral 
immunity to tetanus[11]. B cell counts have been identified as predictive of a memory response to 
vaccination in children with HIV[12]. Although other studies have shown reduced response to 
vaccination in immunosuppressed populations, this is the first study to assess immunological 
predictors of vaccine response in an adult population with systemic vacsulitis on immunosuppressive 
therapy.   
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Previously there has been concern regarding the risk of vaccination triggering a relapse of vasculitis. 
We found no increase in the risk of relapse following vaccination. Similar findings have been 
reported in previous studies of influenza vaccination in AAV patients[10, 13-15]. 
We used conjugate pneumococcal vaccine in this study, as a rapid decrease in antibody levels to the 
polysaccharide vaccine, pneumovax, has been reported in elderly and immunocompromised 
patients[16-18]. In our study patients able to mount an effective immune response maintained 
“protective” antibody responses up to 2 years, suggesting that vaccination remains an important 
preventative measure against infection. However absolute titres of antibody did decline over the 
period of follow up. Similar results were found in  patients with inflammatory arthritis who showed a 
reduction in antibody titres over 18 months[19]. Both these studies suggest that in patients who are 
immunocompromised early revaccination strategies may be required.  
Although vaccination response did not predict infection, those cellular and humoral biomarkers 
predicting poor vaccine response did predict infection in patients with systemic vasculitis in stable 
remission.  Low serum IgG, B cell counts, cumulative steroid exposure and maintenance therapy 
were identified as important risk factors for any infection, but not all-cause mortality, while reduced 
renal function and CD4+ T cell counts additionally increased the risk for severe infection. This study 
suggests the vaccination score provides useful information on the health of the immune system and 
provides a surrogate marker of poor immune  response, which may identify those patients 
potentially benefitting from a reduction in immunosuppression. For those who require long-term 
immunosuppression due to continued disease activity, this data may help identify those patients 
who require additional intervention to reduce risk of infection.  
This study confirmed previous associations between infection and impaired renal function, 
corticosteroid exposure and lymphopenia[20, 21] [22]. We extended these observations by 
demonstrating that CD4 cell counts were associated with severe infection  and reduced B cells and 
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low serum IgG was associated with an increased risk of all infections. Our study differs from previous 
reports[4, 20, 23], in that we did not find a direct association between previous cyclophosphamide 
use and infection. This may reflect the reduced cumulative dose when using pulsed 
cyclophosphamide regimens, which is associated with fewer episodes of leucopoenia compared with 
daily oral cyclophosphamide[24]. We did, however, show a correlation between cyclophosphamide 
exposure and B cell count suggesting that, even in an era of reduced cyclophosphamide use the long 
term impact on the immune system may be important. 
In our study patients at risk of all-cause mortality as predicted by a poor vaccination response have a 
combined deficiency in both the cellular and humoral parts of the immune system. Severe infection 
rates were similar to that seen in primary immunodeficiencies, such as combined variable 
immunodeficiency syndrome (CVID). Immune deficiencies in patients with CVID are characterised by 
a reduced serum IgG, and reduced subsets of B cells and T cells in the peripheral blood[25]. There is 
an increased risk of susceptibility to respiratory infection with encapsulated bacteria[26]. Patients 
with CVID treated with IVIg reconstitution have reduced infection and improved cellular 
immunity[27]. The commonest infection described in patients with systemic vasculitis is respiratory 
tract infection [3].  IVIg replacement may be beneficial for patients with systemic vasculitis and 
recurrent infection, who have low IgG levels, reduced CD4+ and CD19+ lymphocytes and respond 
poorly to vaccination.  
Several limitations of this study require comment. Information on the duration of pneumocystis 
jiroveci prophylaxis was not available in sufficient detail to allow comment on its ability to reduce 
bacterial infection in this cohort. Although vaccination aims to reduce infection, due to the large 
sample size required for such a study and the difficulty in proving bacterial diagnosis this study was 
not powered to investigate changes in infection rates in response to vaccination. Good data exists 
for predictors of infection and mortality and vaccine responses are known to be lower during times 
of intense immunosuppression. We, therefore, focussed on patients who were in sustained 
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remission and had not received induction therapy within the last 6 months and followed them 
prospectively, as little has previously been known about risk factors for infection or all-casue 
mortality in this group. Infection rates in this study are lower than previously reported and reflect 
the reduced immunosuppression used in patients in stable remission and may explain the lack of 
association between vaccination response and infection. We included meningitis vaccination in this 
study, although not standard vaccination for this group, it allowed us to assess both T cell dependent 
and T independent vaccines.  As expected response to the polysaccharide vaccinations were lower 
than to the conjugate vaccines but all patients did respond to a degree. Although this may limit the 
applicability of the vaccine response score, it provided important information on the response to 
polysaccharide vaccines.  
In conclusion, this study identifies older patients with poor renal function and vaccine responses to 
be at highest risk of all-cause mortality.  In addition, those with low B cells and IgG levels had 
greatest risk of infection. Using these biomarkers as risk stratification may allow identification of 
patients who may benefit from immunosuppression withdrawal if appropriate and/or the use of 
additional therapies, such IVIg, as a way to reduce infection and mortality. 
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Table 1 
Median (IQR) or N= 
Patients who received vaccination 
N=92 
Age (years) 66 (53-74) 
Male:Female (n:n) 52:40 
Time since diagnosis (years) 5.7 (2.6-8.7) 
eGFR (ml/min/1.73m2) 62 (38-78) 
Cumulative cyclophosphamide (g) 10 (5-18) 
Cumulative prednisolone (g) 
Median dose prednisolone 
14.2 (8.9-22.1) 
5 (5-10) 
N treated with rituximab 9 
N treated with immunosuppressants  
35 azathioprine 
34 mycophenolate 
17 nil 
 
GPA:MPA:EGPA:PAN (n:n:n:n:n) 59:22:7:4 
Lymphocyte count mm3 (IQR) [normal range] 882 (560 – 1370) [1000-4000] 
CD3 count/mm3 (IQR) [normal range] 675 (385 – 1033) [700-1200] 
CD4 count/mm3 (IQR) [normal range] 373 (229 – 581) [300-1400] 
CD8 count /mm3 244 (144 – 425) [200-900] 
CD19 B cell count mm3 (IQR) [normal range] 30 (10 – 110) [100-500] 
Serum IgG g/L (IQR) [normal range] 8.5 (6.4-10.7) [5.4-16.1] 
 
20 
 
Demographic and therapy and laboratory details of the patients at the time of vaccination. The 
normal ranges reported by the Clinical Immunology Laboratory for peripheral blood lymphocyte, 
CD3, CD4, CD8 and CD19 cell counts and serum IgG are shown in square brackets. Data is shown as 
median (interquartile range). 
Abbreviations:N, number of patients; IQR, interquartile range; eGFR estimated glomerular filtration 
rate using the modified MDRD formula; GPA, granulomatosis with polyangiitis; MPA, microscopic 
polyangiitis;  EGPA, eosinophilic granulomatosis with polyangiitis; PAN, classical polyarteriitis 
nodosa, IgG, immunoglobulin 
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Table 2 
Serotype 
Percentage of patients with antibody titre > 
threshold p= 
Pre-vaccination Post-vaccination 
Pn4 23% 42% <0.001 
Pn6B 48% 67% <0.001 
Pn9V 55% 82% <0.001 
Pn14 55% 74% <0.001 
Pn18C 70% 88% <0.001 
Pn19F 59% 77% <0.001 
Pn23F 50% 74% <0.001 
Men A 33% 79% 0.029 
Men C 9% 54% 0.006 
Men W135 2% 23% 0.4 
Men Y 12% 49% 0.001 
HIb 26% 68% 0.001 
The percentage of patients with antibody titres above the protective threshold pre-vaccination and 
four weeks post vaccination. 
Abbreviations: Pn, pneumococcal serotype, Men, meningitis serotype, HIb, Haemophilus Influenza b 
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Table 3 
Factor Hazard ratio (95% CI) P 
Age (per 10 years) 2.46 (1.12 – 5.38) 0.024 
eGFR (per 10ml/minute) 0.21 (0.08 – 0.57) 0.002 
Vaccine response score (<50% 
response) 
6.01 (1.67 – 21.67) 0.006 
 
Multivariable Cox regression survival analysis of factors associated with mortality. 
Abbreviations: CI, confidence intervals; eGFR, estimated glomerular filtration rate using the modified 
MDRD formula 
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Supplementary table 1 
Serotype Week 0 
titre 
Week 4 
titre 
p= 
Pn4 0.1 (0.1 
- 0.3) 
0.2 (0.1 - 
0.9) 
<0.001 
Pn6B 0.3 (0.1 
- 1.3) 
0.9 (0.3 - 
6.1) 
<0.001 
Pn9V 0.5 (0.1 
- 1.4) 
1.8 (0.6 - 
10) 
<0.001 
Pn14 0.5 (0.1 
- 1.9) 
1.9 (0.3 - 
10) 
<0.001 
Pn18C 1.0 (0.2 
- 3.5) 
4 (1.1 - 
10) 
<0.001 
Pn19F 0.5 (0.2 
- 1.2) 
1.1 (0.4 - 
3.2) 
<0.001 
Pn23F 0.4 (0.1 
- 1.9) 
2.5 (0.4 - 
9.6) 
<0.001 
Men A 1.2 (0.6 
- 2.3) 
4 (1.9 - 
9.2) 
<0.001 
Men C 0.1 (0 - 
0.2) 
1.7 (0.5 - 
8.1) 
<0.001 
Men 
W135 
0 (0 - 
0.1) 
0.2 (0 - 
1.6) 
<0.001 
Men Y 0.2 (0.1 
- 0.6) 
2.4 (0.4 - 
20) 
<0.001 
HIb 0.2 (0 - 
1.1) 
2.3 (0.5 - 
20) 
<0.001 
 
 The antibody titres for the serotypes included in the vaccination regime at week 0 (pre-vaccination) 
and 4 weeks following vaccination. P values are for paired tests comparing week 0 and week 4 
Abbreviation Pn, pneumococcal; Men, meningococcal; HIb, Haemophilous Influenza b 
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Supplementary table 2 
 Percentage of patients with antibody titre > threshold at two years post 
vaccination 
 
Serotype  Patients with antibody titres 
>threshold prevaccination  
Patients with antibody titres <threshold 
pre-vaccination who responded to 
vaccination 
P for Χ2 
Yates’ 
correction 
 
Pn4  80%  62%  ns  
Pn6B  94%  75%  ns  
Pn9V  96%  72%  0.023  
Pn14  98%  100%  ns  
Pn18C  100%  93%  ns  
Pn19F  94%  57%  0.009  
Pn23F  85%  70%  ns  
Men A  98%  66%  0.002 
(0.167)  
MenC  100%  70%  0.031 
(0.079)  
Men 
W135  
100%  88%  ns  
Men Y  94%  82%  ns 
HIb  95%  100%  ns  
 
The percentage of patients with antibody titre above the relevant threshold at two years for patients 
with pre-existing antibodies pre-vaccination and patients without pre-existing antibodies but who 
responded to vaccination demonstrating above threshold titres at 4 weeks post vaccination. 
Abbreviation Pn, pneumococcal; Men, meningococcal; HIb, Haemophilous Influenza b 
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Supplementary Table 3:  
Serotype Baseline 4 weeks 2 years P (baseline 
vs 4 weeks) 
P (4 weeks 
vs 2 years) 
Pn4 0.04 (0.02-0.12) 0.10 (0.05-0.44) 0.10 (0.04-0.30) <0.001 0.006 
Pn6B 0.09 (0.03-0.34) 0.22 (0.07-1.62) 0.22 (0.08-1.01) <0.001 0.009 
Pn9V 0.23 (0.11-0.59) 0.82 (0.25-2.99) 0.74 (0.22-2.05) <0.001 <0.001 
Pn14 0.84 (0.35-3.92) 1.25 (0.61-3.93) 1.17 (0.57-4.31) <0.001 ns 
Pn18C 0.39 (0.15-0.90) 1.31 (0.35-8.23) 1.14 (0.39-4.29) <0.001 0.029 
Pn19F 0.36 (0.15-1.29) 0.54 (0.21-1.57) 0.54 (0.21-2.27) <0.001 ns 
Pn23F 0.37 (0.12-1.19) 1.65 (0.26-4.51) 0.87 (0.23-4.46) <0.001 0.002 
MenA 2.10 (0.9-3.57) 4.32 (2.37-10.00) 4.81 (2.60-10.00) <0.001 ns 
MenC 0.08 (0.04-0.22) 1.03 (0.23-4.27) 0.45 (0.16-1.82) <0.001 <0.001 
MenW135 0.14 (0.08-0.34) 0.36 (0.14-2.41) 0.41 (0.15-1.77) <0.001 ns 
MenY 0.19 (0.09-0.41) 0.66 (0.19-3.88) 0.58 (0.17-1.86) <0.001 0.03 
HIb 1.01 (0.57-2.57) 2.47 (1.19-9.14) 2.69 (1.14-8.01) <0.001 ns 
 
The antibody titres for the serotypes included in the vaccination schedule at baseline, 4 weeks and 2 
years for the 64 patients who had follow up available at 2 years. P values are for paired sample 
analysis (Wilcoxon signed rank test) comparing baseline vs 4 weeks and 4 weeks vs 2 years. ns 
indicates p >0.05. 
Abbreviation Pn, pneumococcal; Men, meningococcal; HIb, Haemophilous Influenza b 
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Supplementary Table 4 
Factor Hazard ratio (95% CI) P 
Age (per 10 years) 2.2 (1.5 - 3.3) <0.001 
eGFR (per 10ml/minute/1.73m2) 0.65 (0.53 – 0.8) <0.001 
Vaccine response score (per 10%) 0.87 (0.76 – 0.995) 0.042 
Severe infection rate per year 5 (1.7 - 14.8) 0.003 
Infection rate per year 1.6 (1.02 – 2.4) 0.039 
Previous cumulative CYC (per g) 0.97 (0.91 – 1.0) 0.277 
Previous cumulative steroids (per g) 1 (0.96-1.04) 0.979 
Continued maintenance 
immunosuppression 
1.7 (0.6 – 4.8) 0.314 
Serum IgG (per g) 1.0 (0.9 – 1.2) 0.633 
B cell count (per 50 cells) 0.8 (0.6 – 1.1) 0.2 
CD4+ count (per 50 cells) 0.9 (0.8 – 1.0) 0.063 
 
Univarable analysis of factors associated with increased risk of mortality during follow up. 
Abbreviations: eGFR, estimated glomerular filtration rate using the modified MDRD formula; CYC, 
cyclophosphamide; IgG, immunoglobulin; g, gramme 
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FIGURE LEGENDS 
Figure 1: Kaplan-Meier survival analysis of patients following vaccination stratified by vaccine 
response score. Patients with the highest vaccine response scores (>50%) had significantly better 
survival than patients with lower vaccine response scores (p=0.025). 
Figure 2 : The effect of continued azathioprine (n=35), mycophenolate (34) or no additional 
immunosuppression (n=17) on MDRD eGFR (A), serum IgG concentration (B), CD19 B cell count (C) 
and CD4 T cell count (D). Patients on no additional immunosuppression had lower eGFR and higher 
serum IgG, B and T cell counts. 
Supplementary Figure 1: The relationships between infection rates per year and serum 
immunoglobulin G (A), CD4 T cells (B) and CD19 B cells (C). 
 Supplementary Figure 2: The relationships between vaccine response scores and serum 
immunoglobulin G (A), CD19 B cells (B),  CD4 T cells (C) and infection rates per year (D). 
 
 
